摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-氯苄基)-1H-吲唑-3-醇 | 1025-60-1

中文名称
1-(4-氯苄基)-1H-吲唑-3-醇
中文别名
——
英文名称
1-(4-Chlorbenzyl)-1H-indazol-3-ol
英文别名
1-(4-Chlor-benzyl)-3-hydroxy-1H-indazol;1-(4-chloro-benzyl)-1,2-dihydro-indazol-3-one;1-(p-Chlorobenzyl)-1H-indazol-3-ol;1-[(4-chlorophenyl)methyl]-2H-indazol-3-one
1-(4-氯苄基)-1H-吲唑-3-醇化学式
CAS
1025-60-1
化学式
C14H11ClN2O
mdl
——
分子量
258.707
InChiKey
CJBXLBPSBLXDJO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    32.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents
    摘要:
    Novel bendazac analogues and their salts have been designed and prepared. The resulting compounds (13c-d, 15c, 17c) showed very good aqueous solubility (> 100 mg/mL). An in vitro assay showed that most of the resulting compounds had potent protective activity against the oxidative damage. Particularly, compound 13d was also able to enhance the WSP and T-AOC level in the H2O2/FeCl3-induced oxidative damage model, indicating the resulting compound may protect the lens through an antioxidant pathway. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.02.061
  • 作为产物:
    描述:
    3-羟基-1H-吲唑4-氯氯苄 在 sodium hydroxide 作用下, 反应 2.0h, 生成 1-(4-氯苄基)-1H-吲唑-3-醇
    参考文献:
    名称:
    Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents
    摘要:
    Novel bendazac analogues and their salts have been designed and prepared. The resulting compounds (13c-d, 15c, 17c) showed very good aqueous solubility (> 100 mg/mL). An in vitro assay showed that most of the resulting compounds had potent protective activity against the oxidative damage. Particularly, compound 13d was also able to enhance the WSP and T-AOC level in the H2O2/FeCl3-induced oxidative damage model, indicating the resulting compound may protect the lens through an antioxidant pathway. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.02.061
点击查看最新优质反应信息

文献信息

  • Methods and compositions of treating a flaviviridae family viral infection
    申请人:Einav Shirit
    公开号:US20100015093A1
    公开(公告)日:2010-01-21
    Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.
    简要概述,本公开的实施例包括化合物、药物组合物、治疗感染黄病毒科病毒的宿主的方法、抑制宿主中HCV复制的方法、抑制NS4B多肽与HCV负链RNA的3′UTR结合的方法、治疗宿主肝纤维化的方法等。
  • METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION
    申请人:Glenn Jeffrey S.
    公开号:US20120148534A1
    公开(公告)日:2012-06-14
    Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.
    简单地说,本公开的实施例包括化合物、药物组合物、治疗感染黄病毒科病毒的宿主的方法、抑制宿主中HCV复制的方法、抑制NS4B多肽与HCV负链RNA的3'UTR结合的方法、治疗宿主肝纤维化的方法等。
  • Knaack, Martin; Fleischhauer, Ilona; Charpentier, Patricia, Liebigs Annalen, 1996, # 9, p. 1477 - 1482
    作者:Knaack, Martin、Fleischhauer, Ilona、Charpentier, Patricia、Emig, Peter、Kutscher, Bernhard、Mueller, Arndt
    DOI:——
    日期:——
  • INDOL-, INDAZOL-, PYRIDOPYRROL- UND PYRIDOPYRAZOL-DERIVATE MIT ANTIASTHMATISCHER, ANTIALLERGISCHER, ENTZÜNDUNGSHEMMENDER UND IMMUNMODULIERENDER WIRKUNG
    申请人:ASTA Medica Aktiengesellschaft
    公开号:EP0775131A2
    公开(公告)日:1997-05-28
  • US5965582A
    申请人:——
    公开号:US5965582A
    公开(公告)日:1999-10-12
查看更多